SCHEMBL10127573

SCHEMBL10127573

Cc1cc(NC(=O)OCc2ccccc2)ccc1C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.48
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
STS P08842 1/20 0.46
BTK Q06187 1/20 0.46
USP30 Q70CQ3 1/20 0.46
GPR119 Q8TDV5 3/20 0.45
MGLL Q99685 1/20 0.45
YAP1 P46937 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
GAA P10253 1/20 0.44
THRB P10828 1/20 0.44
PTPN2 P17706 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4615967 0.94 NAMPT (0.48) NAMPTALDH1A1LMNACYP3A4CYP2D6
SCHEMBL282296 0.89 ALDH1A1 (0.48) NAMPTALDH1A1LMNACYP3A4CYP2D6
SCHEMBL10127693 0.87 NAMPT (0.52) NAMPTSTSUSP30GPR119MGLL
SCHEMBL14824682 0.85 NAMPT (0.65) NAMPTCYP3A4CYP2C9STSGPR119
SCHEMBL10127629 0.85 MGLL (0.51) ALDH1A1BTKMGLLSMN1; SMN2NPC1
SCHEMBL31639792 0.84 ALDH1A1 (0.47) NAMPTALDH1A1LMNACYP3A4CYP2D6
SCHEMBL31333270 0.83 ALDH1A1 (0.45) NAMPTALDH1A1LMNACYP3A4CYP2D6
SCHEMBL4615788 0.82 BTK (0.50) ALDH1A1BTKMGLLHTTSMN1; SMN2
SCHEMBL8030926 0.82 STS (0.47) NAMPTLMNASTSGPR119YAP1
SCHEMBL7043474 0.82 ALDH1A1 (0.60) NAMPTALDH1A1STSGPR119HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 NAMPT 1441/4885ALDH1A1 1554/4885LMNA 2845/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 NAMPT 1441/4885ALDH1A1 1554/4885LMNA 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.